RxDoctor Payments Data

Syed Haider, MD

Internal Medicine · Crystal Lake, ILNPI 1912017898

Payments from drug & device makers

$969in general payments, 2019–2025

Across 64 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$200
  • AbbVie$156
  • Novo Nordisk$114
  • Boehringer Ingelheim$87
  • AstraZeneca$73
  • Zyla Life Sciences, Inc.$53
  • plus $286 from 12 others

What the payments were for

  • Food & beverage$969100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$969 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$193,308
Medicare patients
449
Services billed
2,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$81,924
EliquisApixaban72$77,137
FarxigaDapagliflozin Propanediol46$55,621
MounjaroTirzepatide30$46,262
JardianceEmpagliflozin32$46,214
XareltoRivaroxaban21$34,058
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$29,748
JanuviaSitagliptin Phosphate18$24,169
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$24,158
LinzessLinaclotide16$22,637
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$20,076
Stiolto RespimatTiotropium Br/Olodaterol Hcl31$19,653
Breo ElliptaFluticasone/Vilanterol33$13,027
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$6,845
Atorvastatin Calcium729$6,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$114$81,92460 claims
PfizerEliquis$20$77,13772 claims
Boehringer IngelheimJardiance, Stiolto Respimat$87$65,86763 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta$200$62,85195 claims
AstraZenecaFarxiga$73$55,62146 claims
Johnson & JohnsonXarelto$14$34,05821 claims
MerckJanuvia$19$24,16918 claims
AbbVieLinzess$156$22,63716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Crystal Lake

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →